AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells
Administration Injection type: Intramuscular (IM) or subcutaneous IM injection sites: Deltoid (upper arm), gluteus (buttock), or vastus lateralis (outer thigh) Subcutaneous sites: Abdomen, outer thigh, or back of upper arm Needle gauge: 25-27 gauge for IM, insulin syringe for subcutaneous Timing: Morning or early afternoon is preferred, as the energy boost may interfere with sleep if taken late in the day
Peng X, Hou L, Wu X, Liu Z, Wang Y, Zeng P, et al
It is widely used by people focused on building strength, increasing muscle mass, and improving their power
Integration with rheumatologic care important for systemic inflammatory diseases affecting eyes